Terns Pharmaceutical - About the company
Terns Pharmaceutical is an acquired company based in San Mateo (United States), founded in 2017 by Weidong Zhong. It operates as a Developer of therapies for treating liver disease and cancer. Terns Pharmaceutical has raised $208M in funding from investors like Orbimed, Deerfield and Lilly Asia Ventures. The company has 155 active competitors, including 51 funded and 46 that have exited. Its top competitors include companies like X4 Pharmaceuticals, Forge Biologics and Nimbus Therapeutics.
Company Details
Developer of therapies for treating liver disease and cancer. The lead candidate TERN 101 is a Farnesoid X Receptor agonist (nuclear receptor expressed in high amount), other candidates are TERN 201, TERN 501, and GLP-1R-agonist. These are used for treating Nonalcoholic Steatohepatitis (NASH) and Nonalcoholic Fatty Liver Disease (NAFLD).
- Website
- ternspharma.com
- Social
- Email ID
- *****@ternspharma.com
- Registered Address
- San Mateo (United States)
Key Metrics
Founded Year
2017
Location
San Mateo, United States
Stage
Acquired
Total Funding
$208M in 3 rounds
Latest Funding Round
Ranked
16th among 155 active competitors
Annual Revenue
$1M - $10M as on Dec 31, 2021
Employee Count
60 as on Oct 31, 2026
Similar Companies
Exit Details
Acquired by Merck (Mar 25, 2026)
Legal entities associated with Terns Pharmaceutical
Terns Pharmaceutical is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
Terns Pharmaceuticals, Inc. CIN: 1831363 , United States, Active | $1M - $10M (As on Dec 31, 2021) | - | - | |
TERNS PHARMACEUTICALS, INC. CIN: 001-39926 , United States, Active | Dec 31, 2016 | - | 46 (As on Dec 31, 2022) | - |
Terns Pharmaceutical's acquisition details
Terns Pharmaceutical got acquired by Merck on Mar 25, 2026.
Click here to take a look at Terns Pharmaceutical's acquisition in detail
Sign up to download Terns Pharmaceutical's company profile
Terns Pharmaceutical's funding and investors
Terns Pharmaceutical has raised a total funding of $208M over 3 rounds. Its first funding round was on Apr 2018. Its latest funding round was a Series C round on Jan 05, 2021 for $*****. 6 investors participated in its latest round. Terns Pharmaceutical has 8 institutional investors.
Here is the list of recent funding rounds of Terns Pharmaceutical:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jan 05, 2021 | 7860287 | Series C | 5264008 | 7469124 | 4849597 | 3218997 |
Oct 30, 2018 | 3099960 | Series B | 3443459 | 5804602 | 3749933 | |
Apr 2018 | 5797988 | Series A | 1888922 | 1813788 | 1874777 |
Access funding benchmarks and valuations. Sign up today!View details of Terns Pharmaceutical's funding rounds and investors
Terns Pharmaceutical's founders and board of directors
Founder? Claim ProfileThe founders of Terns Pharmaceutical is Weidong Zhong.
Here are the details of Terns Pharmaceutical's key team members:
- Weidong Zhong: Founder, Director and Chief Scientific Officer of Terns Pharmaceutical.
View details of Terns Pharmaceutical's Founder profiles and Board Members
Terns Pharmaceutical's employee count trend
Terns Pharmaceutical has 60 employees as of Oct 26. Here is Terns Pharmaceutical's employee count trend over the years:
Uncover Terns Pharmaceutical's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Terns Pharmaceutical's Competitors and alternates
Top competitors of Terns Pharmaceutical include X4 Pharmaceuticals, Forge Biologics and Nimbus Therapeutics. Here is the list of Top 10 competitors of Terns Pharmaceutical, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | X4 Pharmaceuticals 2014, Boston (United States), Public | Developer of small molecule drugs for the treatment of cancer | $58.2M | 75/100 | |
2nd |  Forge Biologics 2020, Columbus (United States), Acquired | Developer of gene therapeutic solutions for treating multiple diseases | $330M | 70/100 | |
3rd |  Nimbus Therapeutics 2009, Cambridge (United States), Series F | Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases | $637M | 68/100 | |
4th | Krystal Biotech 2015, Pittsburgh (United States), Public | Developer of genetic medicines to treat rare diseases | $11.3M | 67/100 | |
5th | Madrigal Pharmaceuticals 2011, Conshohocken (United States), Acquired | Develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis | $38.4M | 66/100 | |
6th |  Mammoth 2017, Brisbane (United States), Series D | Provider of molecular diagnostics platform by using CRISPR technology | $271M | 65/100 | |
7th | Developer of a novel treatment for metabolic diseases | $138M | 64/100 | ||
8th | Rigel 1996, San Francisco (United States), Public | Developer of drugs for hematologic disorders, cancer, and rare immune disease | - | 64/100 | |
9th | Intercept Pharmaceuticals 2002, New York City (United States), Acquired | Developer of therapeutics to treat progressive non-viral liver diseases | $121M | 63/100 | |
10th | Innovent Bio 2011, Suzhou (China), Public | Developer of antibody therapeutics for multiple diseases | $535M | 62/100 | |
16th | Terns Pharmaceutical 2017, San Mateo (United States), Acquired | Developer of therapies for treating liver disease and cancer | $208M | 57/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Terns Pharmaceutical's competitors? Click here to see the top ones
Terns Pharmaceutical's Investments and acquisitions
Terns Pharmaceutical has made no investments or acquisitions yet.
Reports related to Terns Pharmaceutical
Here is the latest report on Terns Pharmaceutical's sector:
News related to Terns Pharmaceutical
Filter this listMedia has covered Terns Pharmaceutical for a total of 15 events in the last 1 year, 4 of them have been about company updates and 1 about people movement.
•
Merck Acquires Terns Pharmaceuticals for $6.7 Billion to Enhance Cancer Drug PortfolioWfmz•May 05, 2026•Merck, Terns, Terns Pharmaceutical, terms.com
•
Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for CML TreatmentGlobeNewswire•Apr 27, 2026•Terns Pharmaceutical
•
Masterinvest Kapitalanlage Gmbh Increases Stake In Merck & Co., Inc. $MrkMarketBeat•Apr 18, 2026•Merck, MASTERINVEST, Terns Pharmaceutical, Generali Investments
•
Merck & Co. Deepens Hematology Pipeline with $6.7 Billion Terns AcquisitionChemanager Online•Apr 09, 2026•Terns Pharmaceutical, Merck
•
Merck nears $6 billion acquisition of Terns Pharma to boost cancer portfolio, FT reportsReuters•Mar 25, 2026•Terns Pharmaceutical, Merck, Merck Sharp & Dohme
•
Commodore Capital LP Acquires 5,700,000 Shares in Terns PharmaceuticalsMarketBeat•Mar 15, 2026•Terns Pharmaceutical, Commodore Capital
•
Terns Pharmaceuticals Reports Inducement Grants to New EmployeesGlobeNewswire•Feb 03, 2026•Terns Pharmaceutical
•
Terns Announces Pricing of Upsized $650 Million Public OfferingBusiness Insider•Dec 10, 2025•Terns Pharmaceutical
•
Terns Pharmaceuticals Highlights Positive Phase 1 Data for TERN-701 in CML at ASHGlobeNewswire•Dec 09, 2025•Terns Pharmaceutical
•
Terns Announces Proposed Public OfferingBenzinga•Dec 09, 2025•Terns Pharmaceutical, Cowen, Leerink Partners, Mizuho Financial Group and 4 others
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Terns Pharmaceutical
Explore our recently published companies
- Gonzalez Home Improvement - United States based, Unfunded company
- Freerange Creatives - Cape Town based, 2016 founded, Unfunded company
- Corporation for Entrepreneurship and - Cullowhee based, 2015 founded, Unfunded company
- Pave Espania - Gurugram based, 1999 founded, Unfunded company
- Upwrite - India based, 2017 founded, Unfunded company
- B3 Home Improvement - Unfunded company
